Find out now if you qualify. Time is limited to file a claim. You may be entitled to compensation. Fill out the form below to see if you qualify.
Free Claim Review
By clicking the “Submit” button below, I hereby grant my express written consent and authorize Tort Group LLC, and its affiliates and law firm partners, to contact me about their services at the phone number and email address provided above/below. I consent to receive telemarketing calls and text messages using an automatic telephone dialing system or prerecorded voice. I understand that the express written consent I provide here is not required in order to purchase any good or service. I also acknowledge and agree to the Terms & Conditions. Text Message frequency may vary. Message & Data rates may apply. You may opt-out of SMS at any time by replying STOP to the phone number we texted you from. Reply HELP for help to the phone number we texted you from.. You may view our Privacy Policy here.
We are here to listen and help.
Submit below to speak with our team.
Ronnie Roman Sexual Abuse Claim Help
Meningioma Claims
Justice & Compensation Help
Meningioma Tumors & the Depo-Provera Shot
Information submitted will be transmitted to a law firm. This communication is intended to be an attorney-client communication for purposes of evaluating your claim and will be kept confidential by the law firm. The communication does not create an attorney-client relationship and no relationship is formed until a fee agreement is signed by you and the law firm. I also have read and agree to your Privacy Policy
File Your Claim Now
April 2022: The MDL Paraquat class action judge will have a status conference on April 1st to review where the litigation is headed and how best to take the bellwether lawsuits forward for trial in November 2022. 44 new paraquat lawsuits have been added to the MDL in the last two weeks. At this pace, April 2022 will be the busiest month for new files yet. Last week, the parties filed their class-action bellwether picks with the Paraquat MDL judge. Those choices, however, have not been made public.
May 2022: In the last month, over 50 new cases have been added to the Paraquat Lawsuit Multidistrict Litigation (MDL). A group of six patients was recently selected by the Paraquat MDL court for the initial Paraquat Parkinson's disease bellwether trials. As a result, the first trial in November 2022 is approaching soon. The strategy is to select 16 paraquat claims from among the almost 1000 Parkinson's disease litigation claims filed. Following some limited fact discovery in these instances, paraquat attorneys on both sides submitted a preference list to the MDL court, ranking the 16 cases in order of priority. Attorneys for plaintiffs seek the finest facts for their clients, while defense attorneys want the worst. The judge whittled the list down to six Paraquat claims based on these rankings.
CLAIM UPDATES
We are here to listen and help answer all your questions. Contact us today for a Free Claim Review by filling out the form above.
Studies & Settlements
Anyone who has been diagnosed with a brain tumor after taking the Depo-Provera shot(DMPA) for over a year should contact us now. Seek the justice and closure you deserve.
Significant compensation may be available. Free Claim Review.
Seek Justice Today
Maryland Juvenile Detention
Abuse Claim Help
Jeff Brandow
Sexual Abuse
Claim Help
File Your Claim Now
Birth control shots including the Depo-Provera shot, Depo-SubQ Provera shot, and medroxyprogesterone shot, are widely used hormonal contraceptives, that have been the subject of scrutiny regarding potential health risks, including a possible association with brain tumors. Depo-Provera, containing the progestin depot medroxyprogesterone acetate (DMPA), is administered via injection every three months to prevent pregnancy. While it is considered an effective contraceptive option, recent studies have raised concerns about its long-term safety profile, particularly concerning its association with brain tumors.
A case-control study published in Cancer Research in 2021 highlighted a possible correlation between progestin-based contraceptives, like Depo-Provera, and an increased risk of certain types of brain tumors, including meningiomas (Smith et al., 2021). Meningiomas are typically benign but can be serious due to their location and potential for causing neurological symptoms. The study suggested that progestins might influence tumor growth due to their impact on hormonal pathways involved in cell proliferation.
"Trust our experienced team to handle your claim with care and commitment. Contact us today for reliable legal support."
Our dedicated team will fight for your rights and compensation. Confidentiality, Safety, & Justice are our top priorities
How to Qualify for a Depo-Provera Claim:
Use of Depo-Provera
Diagnosis of Brain Tumor
Document Evidence
Submit The Form Above
Depo-Provera is an injectable birth control containing the synthetic hormone medroxyprogesterone acetate, is linked to an increased risk of meningioma, a rare brain tumor. This risk was not adequately disclosed to consumers or medical professionals. Studies, including those published in the Journal of the American Medical Association (JAMA), have shown that long-term use of Depo-Provera significantly raises the risk of developing meningiomas.
Claims against Pfizer, Inc., the drug’s manufacturer, alleges that the company knew or should have known about the increased risk of meningiomas—brain tumors that can cause severe neurological symptoms—especially with prolonged use. The claims state that Pfizer failed to adequately warn doctors and patients, rushed the drug to market without sufficient long-term studies, and prioritized profits over safety.
Due to the rising number of claims against Pfizer regarding Depo-Provera and brain tumors have been consolidated into multidistrict litigation (MDL) in federal court. Affected individuals may seek compensation for medical expenses, long-term care, and other damages, with the potential for federal court consolidation of cases.
While Pfizer has not admitted liability in any of these cases, it has quietly settled some lawsuits, particularly those involving long-term users diagnosed with brain tumors. Confidential settlement agreements prevent the disclosure of compensation amounts, but they reflect the increasing attention to this issue.
Early research into the safety of DMPA largely focused on its impact on bone density and cardiovascular health. However, more recent studies have expanded the scope to examine its potential links to cancer. A notable study conducted by the National Cancer Institute (NCI) reviewed the effects of hormonal contraceptives on various cancer types, including brain tumors. The study found that there were indications that long-term use of DMPA might be associated with an increase in risk (Baker, 2022).
Anyone who has used the Depo-Provera shot for at least one year and has developed a Brain Tumor or Meningioma, please contact us immediately to start a claim.
Deadline to file is approaching.
